Excessive endurance exercise training (EEET) is accompanied by cardiac remodeling, changes in ventricular function and increased
heart failure risk.
Fasudil, a potent
Rho-kinase inhibitor, has been demonstrated to blunt cardiomyocyte
hypertrophy, cardiac remodeling, and
heart failure progression in pre-clinical trials and has been approved for clinical use in Japan. We examined the in vivo bioefficacy of
fasudil against EEET-induced cardiac remodeling and the underlying molecular mechanisms. Male Sprague-Dawley rats were randomly divided into three groups: sedentary control (SC), EEET, and EEET with
fasudil treatment (EEET-F). Rats in EEET and EEET-F groups ran on a motorized treadmill for 12 weeks. The results revealed that EEET increased myocardial
hypertrophy (LV weight/tibial length), myocyte cross-sectional area,
hypertrophy-related pathways (
IL6/STAT3-MEK5-ERK5,
calcineurin-
NFATc3, p38 and JNK MAPK), hypertrophic markers (
ANP/BNP), pro-apoptotic molecules (
cytochrome C, cleaved
caspase-3 and PARP), and
fibrosis-related pathways (
FGF-2-ERK1/2) and
fibrosis markers (uPA,
MMP-9 and -2). These pathways were then expressed lower in the EEET-F group when compared with the EEET group. The cardiac hypertrophic level, apoptotic pathway and
fibrosis signaling were further inhibited in the
fasudil-treated group. We systematically investigated the possible signaling pathways leading to EEET-induced
cardiac hypertrophy, apoptosis and
fibrosis. We also provide evidence for the novel function of
fasudil in suppressing EEET-induced cardiac remodeling and impairment by multiple mechanisms, which suggests that the RhoA signaling pathway contributes to EEET-induced cardiac remodeling and dysfunction.